证券代码：688212 证券简称：澳华内镜 公告编号：2025-072 上海澳华内镜股份有限公司 关于控股股东、实际控制人权益变动触及 5%整数倍刻 度的提示性公告 顾康、顾小舟及其控制的企业上海小洲光电科技有限公司保证向本公司提供的信 息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏，并对其内容的真实性、 准确性和完整性依法承担法律责任。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少☑ | | --- | --- | --- | --- | | 权益变动前合计比例 | 31.36% | | | | 权益变动后合计比例 | 30.00% | | | | 本次变动是否违反已作出的承 | 是□ | 否☑ | | | 诺、意向、计划 | | | | | 是否触发强制要约收购义务 | 是□ | 否☑ | | 注：上表中"权益变动前合计比例"是以上海澳华内镜股份有限公司（以下简称"公司"） 首次公开发行股票并在科创板上市日的持股情况和总股本进行计算，"权益变动后合计比例" 根据公司当前总股本计算得出。 一、信息披露义务人及其 ...

- No quantitative models or factors were mentioned in the provided content

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][48]. Core Insights - The pharmaceutical sector has shown stronger performance compared to the overall market, with a 3.29% increase in the biopharmaceutical sector, while the total A-share market declined by 0.09% [1][36]. - The report highlights a significant divergence in performance among different segments of the medical device market, with consumables growing faster than equipment and IVD products [2][19]. - The report emphasizes the long-term growth potential of the Chinese medical device market despite short-term challenges related to pricing and policy [2][20]. Summary by Sections Market Performance - The biopharmaceutical sector outperformed the overall market, with notable increases in various sub-sectors: chemical pharmaceuticals up 4.51%, bioproducts up 2.65%, medical services up 1.81%, medical devices up 1.77%, and traditional Chinese medicine up 4.08% [1][36]. Key Companies and Predictions - Major companies such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital are rated as "Outperform" with projected net profits for 2024 ranging from 1.4 billion to 116.7 billion CNY [4][48]. - Mindray Medical is highlighted for its strong R&D and sales capabilities, benefiting from domestic medical infrastructure and international expansion [48]. - WuXi AppTec is recognized for its comprehensive drug development services, poised to benefit from the rapid growth of the global drug development outsourcing market [48]. Investment Strategy - The report suggests focusing on undervalued stocks in the medical device and pharmacy sectors, which have already reflected risks from policies like centralized procurement [46][47]. - It recommends monitoring the clinical progress of innovative drugs overseas and emphasizes the importance of global clinical data for commercialization [47][48]. Recommended Stocks - The report lists several recommended stocks, including Mindray Medical, WuXi AppTec, Aier Eye Hospital, and others, indicating their strong market positions and growth potential [48][49].

- The report does not contain any information about quantitative models or factors.

Core Insights - The overall enthusiasm for A-share research remains high, with 125 public fund institutions participating in research activities covering 132 stocks across 22 industries, totaling 707 research instances during the week of November 10-16, 2025 [1][2] Group 1: Company Focus - Industrial Fulian, a leading consumer electronics company with a market value in the trillions, was the most favored by public funds, attracting 48 institutions for research, focusing on its global expansion process [1][2] - Other notable companies include Aobi Zhongguang, which received 15 research instances, with institutions primarily interested in its self-developed chip advancements [1] Group 2: Industry Analysis - The electronics, machinery, and pharmaceutical industries were the most researched, each exceeding 100 research instances, with the electronics sector leading at 115 instances covering 18 stocks [2][3] - The machinery industry followed closely with 111 research instances across 16 stocks, while the pharmaceutical industry ranked third with 102 instances covering 8 stocks [3] Group 3: Institutional Participation - Guotai Fund was the most active, conducting 18 research instances covering 18 stocks, primarily in the power equipment, machinery, and pharmaceutical sectors [3] - Huaxia Fund and Huitianfu Fund both conducted 17 research instances, with Huaxia focusing more on machinery and Huitianfu leaning towards electronics and machinery [3]

证券代码：688212 证券简称：澳华内镜 公告编号：2025-071 会议召开时间：2025 年 11 月 26 日（星期三）13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 19 日（星期三）至 11 月 25 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （ir@aohua.com）进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 上海澳华内镜股份有限公司（以下简称"公司"）已于 2025 年 10 月 29 日 发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 26 日（星期三） 13:00-14:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 上海澳华内镜股份有限公司 关于召开 2025 年第三季度业绩说明 ...

上海市通力律师事务所关于上海澳华内镜股份有限公司 2025 年第三次临时股东大会的法律意见书 致:上海澳华内镜股份有限公司 上海市通力律师事务所(以下简称"本所")接受上海澳华内镜股份有限公司(以 下简称"公司"）的委托,指派本所茹秋乐律师、章唐乾律师(以下简称"本所律师") 根据《中华人民共和国公司法》《中华人民共和国证券法》等法律法规和规范性文件(以 下统称"法律法规")及《上海澳华内镜股份有限公司章程》(以下简称"公司章程") 的规定就公司 2025 年第三次临时股东大会（以下简称"本次股东大会"）相关事宜出 具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以 了核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中 的所有签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、 完整和有效的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股东大会 人员资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表 意见,并不对本次股东大会所审议的议案内容 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2025-070 上海澳华内镜股份有限公司 2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次会议由公司董事会召集，董事长顾康先生因工作行程冲突原因未能出席 会议，经公司半数以上董事推举，本次会议由公司董事陈鹏先生主持。本次会议 采用现场投票与网络投票相结合的方式进行表决。本次会议的召集、召开及表决 程序符合《公司法》《证券法》及《公司章程》的相关规定。 （五） 公司董事和董事会秘书的出席情况 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 14 日 （二） 股东大会召开的地点：上海市闵行区光中路 133 弄 66 号澳华内镜大厦十 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 186 | | --- | --- | | 普通股股东人数 | 186 | | ...

Group 1 - The pharmaceutical and biotechnology industry is currently presenting structural opportunities, particularly in the endoscope sector with new products set to launch, including Olympus X1 and other high-end products, which are expected to drive a new wave of equipment replacement demand [1] - The medical device sector remains highly prosperous, with average bidding growth rates exceeding 30% for ultrasound and CT subcategories from December 2024 to September 2025, and a performance inflection point is anticipated in 2026 as industry inventory returns to normal levels [1] - In the innovative drug sector, 127 new drugs outside the national medical insurance negotiation list are expected to be added by 2025, alongside the expansion of commercial insurance for innovative drugs, indicating continuous improvement in payment mechanisms [1] Group 2 - The vaccine ETF (159643) tracks the vaccine biotechnology index (980015), which selects listed companies involved in bioproducts, life science tools, and services, focusing on vaccine research, production, and related services [1] - The constituent stocks of the index exhibit significant innovation and growth characteristics, reflecting the overall performance and technological development dynamics of the vaccine and biotechnology industry [1]

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - The company's performance meets expectations, with a revenue inflection point observed. In Q3 2025, the company reported revenue of 162 million yuan, a year-on-year increase of 10.37%, marking a return to positive growth for the quarter. However, the net profit attributable to the parent company was -15 million yuan, a decrease of 148.44% year-on-year, primarily due to changes in product mix affecting gross margin and a high base effect from 2024 [2][4][11]. - The new product AQ-400 is expected to enter a ramp-up phase, featuring advanced imaging technology and capabilities that could enhance the company's competitive edge in the market, particularly in tertiary hospitals [11]. - The company is focusing on expanding its overseas market presence, particularly in high-end models, with established marketing support centers in Europe and other regions, which is anticipated to drive rapid growth in international business [11]. - Future profit projections for the company are optimistic, with expected net profits of 11 million yuan, 49 million yuan, and 140 million yuan for 2025, 2026, and 2027, respectively [11]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported total revenue of 423 million yuan, a year-on-year decrease of 15.57%. The net profit attributable to the parent company was -56 million yuan, down 250.37% year-on-year. In Q3 2025, revenue was 162 million yuan, up 10.37% year-on-year, while the net profit was -15 million yuan, a decrease of 148.44% [4][11]. Product Development - The AQ-400 product features significant upgrades, including 3D imaging technology, EDOF functionality, and a high-spectral optical staining platform, which are expected to create a differentiated competitive advantage and increase market share in tertiary hospitals [11]. Market Expansion - The company is actively deepening its presence in overseas markets, with a focus on high-end products. It has made progress in market access in Europe and is expanding coverage in regions such as Brazil, South Korea, and Malaysia [11].